Начало › Рак на белия дроб › Северна Каролина › Durham
Клинични проучвания за Рак на белия дроб в Durham, NC
32 проучвания за Рак на белия дроб търсят участници в обекти в и около Durham (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Набиране на участнициФаза 3
- Duke University Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Набиране на участнициФаза 1/2
- Duke University, Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- Durham VA Medical Center, Durham
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Набиране на участнициФаза 3
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Набиране на участнициФаза 3
- Duke Cancer Center, Durham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Набиране на участнициФаза 3
- UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · на 10 мили
A Study of PHN-012 in Patients With Advanced Solid Tumors
Набиране на участнициФаза 1
- PHN-012-001 Site, Durham
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Набиране на участнициФаза 3
- Duke University Medical Center, Durham
Study of Trilaciclib and Lurbinectidin
Набиране на участнициФаза 2
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill · на 10 мили
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
Набиране на участнициФаза 2
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · на 10 мили
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Набиране на участнициФаза 1/2
- Duke University School of Medicine, Durham
Effects of Infusion Timing on Treatment Response in Solid Tumors
Набиране на участнициФаза 2
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill · на 10 мили
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · на 10 мили
The Vanguard Study: Testing a New Way to Screen for Cancer
Набиране на участнициЗдравите доброволци са добре дошли
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 мили
Health Education Approach to Lung Screening
Набиране на участнициЗдравите доброволци са добре дошли
- University of North Carolina-Chapel Hill, Carrboro · на 11 мили
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 мили
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Набиране на участнициФаза 1
- Xencor Investigative Site, Durham
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Набиране на участнициФаза 1/2
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · на 10 мили
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Набиране на участници
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · на 10 мили
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Набиране на участнициФаза 2
- University of North Carolina, Chapel Hill · на 10 мили
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Набиране на участнициФаза 1
- Research Site, Durham
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Durham VA Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Набиране на участнициФаза 1
- Duke Cancer Center, Durham
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Набиране на участнициФаза 1/2
- University of North Carolina at Chapel Hill, Chapel Hill · на 10 мили
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2/3
- Durham VA Medical Center, Durham
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
Набиране на участнициЗдравите доброволци са добре дошли
- Duke University, Durham
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Набиране на участници
- Durham VA Medical Center, Durham, NC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Набиране на участнициФаза 1
- Duke Cancer Institute, Durham
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
Набиране на участнициРанна фаза 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 мили
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, Chapel Hill · на 10 мили
UNC Pleural Fluid Registry
Набиране на участнициНаблюдателно проучване
- UNC Lingeberger Comprehensive Cancer Center, Chapel Hill · на 10 мили
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Набиране на участнициФаза 2
- University of North Carolina, Chapel Hill · на 10 мили
Проучвания за Рак на белия дроб в други градове
- Houston, TX78 проучвания
- Boston, MA62 проучвания
- New York City, NY60 проучвания
- Los Angeles, CA45 проучвания
- Washington, DC41 проучвания
- Arlington, VA41 проучвания
- Chicago, IL41 проучвания
- Nashville, TN40 проучвания
- Baltimore, MD40 проучвания
- St. Louis, MO39 проучвания
- Columbus, OH37 проучвания
- Philadelphia, PA36 проучвания
Други проучвания в Durham
- Рак на гърдата63 проучвания
- Рак (всички видове)58 проучвания
- Рак на белия дроб с недребноклетъчен тип39 проучвания
- Множествен миелом37 проучвания
- Метастатичен рак33 проучвания
- Остра миелоидна левкемия33 проучвания
- Рак на простатата32 проучвания
- Колоректален рак28 проучвания
- Хронична лимфоцитна левкемия27 проучвания
- Рак на яйчниците27 проучвания
- Сърдечна недостатъчност26 проучвания
- Рак на панкреаса24 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.